Translational regulation of utrophin by miRNAs.

PLoS One

Department of Physiology, Pennsylvania Muscle Institute, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Published: May 2012

Background: Utrophin is the autosomal homolog of dystrophin, the product of the Duchenne Muscular Dystrophy (DMD) locus. Its regulation is of therapeutic interest as its overexpression can compensate for dystrophin's absence in animal models of DMD. The tissue distribution and transcriptional regulation of utrophin have been characterized extensively, and more recently translational control mechanisms that may underlie its complex expression patterns have begun to be identified.

Methodology/principal Findings: Using a variety of bioinformatic, molecular and cell biology techniques, we show that the muscle isoform utrophin-A is predominantly suppressed at the translational level in C2C12 myoblasts. The extent of translational inhibition is estimated to be ~99% in C2C12 cells and is mediated by both the 5'- and 3'-UTRs of the utrophin-A mRNA. In this study we identify five miRNAs (let-7c, miR-150, miR-196b, miR-296-5p, miR-133b) that mediate the repression, and confirm repression by the previously identified miR-206. We demonstrate that this translational repression can be overcome by blocking the actions of miRNAs, resulting in an increased level of utrophin protein in C2C12 cells.

Conclusions/significance: The present study has identified key inhibitory mechanisms featuring miRNAs that regulate utrophin expression, and demonstrated that these mechanisms can be targeted to increase endogenous utrophin expression in cultured muscle cells. We suggest that miRNA-mediated inhibitory mechanisms could be targeted by methods similar to those described here as a novel strategy to increase utrophin expression as a therapy for DMD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246502PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0029376PLOS

Publication Analysis

Top Keywords

utrophin expression
12
regulation utrophin
8
inhibitory mechanisms
8
mechanisms targeted
8
utrophin
7
translational
5
translational regulation
4
mirnas
4
utrophin mirnas
4
mirnas background
4

Similar Publications

Duchenne muscular dystrophy (DMD) is caused by mutations in the gene encoding dystrophin, a subsarcolemmal protein whose absence results in increased susceptibility of the muscle fiber membrane to contraction-induced injury. This results in increased calcium influx, oxidative stress, and mitochondrial dysfunction, leading to chronic inflammation, myofiber degeneration, and reduced muscle regenerative capacity. Fast glycolytic muscle fibers have been shown to be more vulnerable to mechanical stress than slow oxidative fibers in both DMD patients and DMD mouse models.

View Article and Find Full Text PDF
Article Synopsis
  • X-linked recessive dystrophinopathies are common muscular dystrophies in both humans and dogs, with 20 specific variants identified in dogs, including one in Border Collies.
  • A 5-month-old male Border Collie was diagnosed with mild dystrophin-deficient muscular dystrophy associated with a new variant in the dystrophin gene, discovered through various neurological and laboratory examinations.
  • The identified mutation caused a significant reduction in dystrophin mRNA and protein levels, but the affected dog has shown clinical stabilization by 6 months and remains stable at 2 years old, despite the typically poor prognosis for the condition.
View Article and Find Full Text PDF

Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy.

Neurol Int

July 2024

Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.

Significant progress has been achieved in understanding Duchenne muscular dystrophy (DMD) mechanisms and developing treatments to slow disease progression. This review article thoroughly assesses primary and secondary DMD therapies, focusing on innovative modalities. The primary therapy addresses the genetic abnormality causing DMD, specifically the absence or reduced expression of dystrophin.

View Article and Find Full Text PDF

Unlabelled: The injectisome encoded by pathogenicity island 2 (SPI-2) had been thought to translocate 28 effectors. Here, we used a proteomic approach to characterize the secretome of a clinical strain of invasive non-typhoidal serovar Enteritidis that had been mutated to cause hyper-secretion of the SPI-2 injectisome effectors. Along with many known effectors, we discovered the novel SseM protein.

View Article and Find Full Text PDF

Duchenne muscular dystrophy (DMD) is a lethal muscle disease caused by the absence of the protein dystrophin. Dystrophin is hypothesized to work as a molecular shock absorber that limits myofiber membrane damage when undergoing reversible unfolding upon muscle stretching and contraction. Utrophin is a dystrophin homologue that is under investigation as a protein replacement therapy for DMD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!